Eli Lilly CEO Opposes Drug Pricing Legislation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: seekingalpha
- Opposition to Pricing Legislation: Eli Lilly CEO Dave Ricks stated that the company opposes codifying pricing agreements made with the Trump administration into law, arguing that the congressional process could yield unfavorable outcomes that jeopardize new drug development and the vitality of the U.S. pharmaceutical industry.
- Policy Concerns: Ricks emphasized that many focus on reducing drug prices today without considering the implications for future drug research, which he believes could have long-term negative effects on the U.S. pharmaceutical sector, and Lilly will use all available tools to combat what they view as bad policy.
- Industry Consensus: Lilly has reached agreements with several major pharmaceutical companies, including Novartis and Bristol Myers Squibb, to lower drug prices, highlighting the complex attitudes within the industry regarding pricing policies and reflecting divisions in drug policy formulation.
- New Drug Development Updates: Recently, Eli Lilly received approval for its weight loss drug orforglipron, demonstrating the company's ongoing commitment to new drug development, even as it faces policy challenges, and aims to expand its global market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 919.770
Low
950.00
Averages
1192
High
1500
Current: 919.770
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Shares Near $900, Stock Split Speculation Grows
- Stock Price Near $900: Eli Lilly's shares are hovering just below the $900 mark, reflecting market confidence in its future growth, with speculation about a stock split potentially attracting a broader investor base.
- Strong Drug Sales Growth: The company's GLP-1 drugs, Mounjaro and Zepbound, are projected to generate nearly $23 billion and $13.5 billion in revenue respectively for 2025, with year-over-year growth rates of 99% and 175%, indicating robust market demand and significant growth potential.
- Low Market Penetration: Despite strong adoption, GLP-1 drug penetration among the eligible obesity population in the U.S. remains in the mid-single digits, suggesting substantial growth opportunities for Eli Lilly's obesity portfolio, especially with the upcoming launch of oral GLP-1 therapy orforglipron.
- Optimistic Future Revenue Outlook: Eli Lilly is guiding for fiscal 2026 revenue between $80 billion and $83 billion, and while management anticipates pricing pressures on revenue growth, strong volume growth is expected to more than offset this, highlighting the broad-based and durable demand for its drugs.
See More
Eli Lilly Secures FDA Approval for New Weight-Loss Drug
- FDA Approval: Eli Lilly announced that its weight-loss drug Foundayo received FDA approval, becoming the first daily oral weight-loss medication, which is expected to be highly popular and pushed the stock price up nearly 4%, significantly outperforming the S&P 500's 0.7% gain.
- Product Launch Plan: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, likely attracting many consumers seeking weight-loss solutions and further increasing the company's market share.
- Market Competition Analysis: Compared to Novo Nordisk's Wegovy, Foundayo has lower reported weight-loss results in clinical trials, but its more stable molecule and flexible dosing schedule may make it more appealing to consumers, enhancing its competitive edge in the market.
- Significant Marketing Potential: Eli Lilly possesses substantial marketing resources, which are expected to effectively drive the acceptance of Foundayo in the market; combined with its leadership position in the weight-loss drug sector, this could lead to a notable increase in stock price.
See More
Eli Lilly Wins FDA Approval for Foundayo Weight-Loss Pill
- FDA Approval: Eli Lilly has received FDA approval for its weight-loss drug Foundayo, which is a daily oral medication, marking a significant breakthrough for the company in the weight-loss market and is expected to attract a large consumer base.
- Positive Market Reaction: The announcement led to a nearly 4% increase in Eli Lilly's stock price, significantly outperforming the S&P 500's 0.7% gain, indicating strong investor confidence in the new product.
- Clear Product Advantages: Foundayo offers a sturdier molecular structure and more flexible dosing compared to Novo Nordisk's Wegovy, although it has shown slightly lower weight-loss results in clinical trials; however, its convenience may attract more users.
- Innovative Sales Channel: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, which is expected to enhance the company's market share and brand influence.
See More
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
Trump to Address the Nation on Iran War Tonight
- Speech Timing: President Trump is scheduled to address the nation at 9 p.m. ET regarding the Iran war, where he is expected to elaborate on U.S. strategies and policies in the region.
- Public Interest: This speech is likely to attract significant public and media attention, especially against the backdrop of current international tensions, potentially influencing public perception of government foreign policy.
- Tesla Delivery Schedule: Tesla is expected to release its latest delivery figures early Thursday, which will provide investors with crucial insights into the company's performance and market demand.
- Market Reaction Anticipation: Trump's speech and Tesla's delivery data may impact the stock market, particularly as investors closely monitor geopolitical risks related to Iran and dynamics in the electric vehicle market.
See More
Eli Lilly's Foundayo Weight-Loss Pill Approved by FDA
- Drug Approval: Eli Lilly's new daily weight-loss pill, Foundayo, has received FDA approval, containing orforglipron, with clinical trials showing an average weight loss of 12% over 72 weeks, significantly enhancing competition in the obesity treatment market.
- Pricing and Dosage: Foundayo will be available in six different dosages, priced between $149 and $349 monthly for uninsured patients, increasing its market appeal and likely attracting many consumers seeking weight-loss solutions.
- Convenience of Use: Unlike injectable obesity medications, Foundayo can be taken at any time of day without food, greatly enhancing user convenience, which may boost market acceptance and sales.
- Future Prospects: Eli Lilly plans to seek approval for orforglipron to treat Type 2 diabetes later this year, as studies indicate it helps improve blood sugar control in diabetic patients, further expanding its market potential.
See More
Eli Lilly Shares Near $900, Stock Split Speculation Grows
- Stock Price Near $900: Eli Lilly's shares are hovering just below the $900 mark, reflecting market confidence in its future growth, with speculation about a stock split potentially attracting a broader investor base.
- Strong Drug Sales Growth: The company's GLP-1 drugs, Mounjaro and Zepbound, are projected to generate nearly $23 billion and $13.5 billion in revenue respectively for 2025, with year-over-year growth rates of 99% and 175%, indicating robust market demand and significant growth potential.
- Low Market Penetration: Despite strong adoption, GLP-1 drug penetration among the eligible obesity population in the U.S. remains in the mid-single digits, suggesting substantial growth opportunities for Eli Lilly's obesity portfolio, especially with the upcoming launch of oral GLP-1 therapy orforglipron.
- Optimistic Future Revenue Outlook: Eli Lilly is guiding for fiscal 2026 revenue between $80 billion and $83 billion, and while management anticipates pricing pressures on revenue growth, strong volume growth is expected to more than offset this, highlighting the broad-based and durable demand for its drugs.
See More
Eli Lilly Secures FDA Approval for New Weight-Loss Drug
- FDA Approval: Eli Lilly announced that its weight-loss drug Foundayo received FDA approval, becoming the first daily oral weight-loss medication, which is expected to be highly popular and pushed the stock price up nearly 4%, significantly outperforming the S&P 500's 0.7% gain.
- Product Launch Plan: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, likely attracting many consumers seeking weight-loss solutions and further increasing the company's market share.
- Market Competition Analysis: Compared to Novo Nordisk's Wegovy, Foundayo has lower reported weight-loss results in clinical trials, but its more stable molecule and flexible dosing schedule may make it more appealing to consumers, enhancing its competitive edge in the market.
- Significant Marketing Potential: Eli Lilly possesses substantial marketing resources, which are expected to effectively drive the acceptance of Foundayo in the market; combined with its leadership position in the weight-loss drug sector, this could lead to a notable increase in stock price.
See More
Eli Lilly Wins FDA Approval for Foundayo Weight-Loss Pill
- FDA Approval: Eli Lilly has received FDA approval for its weight-loss drug Foundayo, which is a daily oral medication, marking a significant breakthrough for the company in the weight-loss market and is expected to attract a large consumer base.
- Positive Market Reaction: The announcement led to a nearly 4% increase in Eli Lilly's stock price, significantly outperforming the S&P 500's 0.7% gain, indicating strong investor confidence in the new product.
- Clear Product Advantages: Foundayo offers a sturdier molecular structure and more flexible dosing compared to Novo Nordisk's Wegovy, although it has shown slightly lower weight-loss results in clinical trials; however, its convenience may attract more users.
- Innovative Sales Channel: The new drug will start shipping on April 6 through Eli Lilly's LillyDirect online sales platform, with a minimum self-pay option of $149 per month, which is expected to enhance the company's market share and brand influence.
See More
US Stocks Close Higher Amid Optimism Over Middle East Conflict Resolution
- Market Rally: The S&P 500 rose by 0.72%, the Dow Jones increased by 0.48%, and the Nasdaq 100 climbed by 1.18%, reflecting growing investor optimism regarding a potential resolution to the Middle East conflict, which has bolstered market confidence.
- Strong Economic Data: The US ADP employment change for March increased by 62,000, surpassing expectations of 40,000, while February retail sales rose by 0.6% month-over-month, indicating robust economic recovery that could influence Federal Reserve policy decisions.
- Interest Rate Expectations: Despite positive economic indicators, hawkish comments from St. Louis Fed President raised concerns about inflation and employment, leading to a mere 1% chance of a 25 basis point rate hike at the upcoming April FOMC meeting, reflecting cautious market sentiment.
- Divergent Stock Performances: Target Hospitality surged over 36% after securing a multi-year contract worth over $550 million, while Nike fell more than 15% due to revenue forecasts indicating a decline, highlighting the market's varied outlook on different companies' futures.
See More
Trump to Address the Nation on Iran War Tonight
- Speech Timing: President Trump is scheduled to address the nation at 9 p.m. ET regarding the Iran war, where he is expected to elaborate on U.S. strategies and policies in the region.
- Public Interest: This speech is likely to attract significant public and media attention, especially against the backdrop of current international tensions, potentially influencing public perception of government foreign policy.
- Tesla Delivery Schedule: Tesla is expected to release its latest delivery figures early Thursday, which will provide investors with crucial insights into the company's performance and market demand.
- Market Reaction Anticipation: Trump's speech and Tesla's delivery data may impact the stock market, particularly as investors closely monitor geopolitical risks related to Iran and dynamics in the electric vehicle market.
See More
Eli Lilly's Foundayo Weight-Loss Pill Approved by FDA
- Drug Approval: Eli Lilly's new daily weight-loss pill, Foundayo, has received FDA approval, containing orforglipron, with clinical trials showing an average weight loss of 12% over 72 weeks, significantly enhancing competition in the obesity treatment market.
- Pricing and Dosage: Foundayo will be available in six different dosages, priced between $149 and $349 monthly for uninsured patients, increasing its market appeal and likely attracting many consumers seeking weight-loss solutions.
- Convenience of Use: Unlike injectable obesity medications, Foundayo can be taken at any time of day without food, greatly enhancing user convenience, which may boost market acceptance and sales.
- Future Prospects: Eli Lilly plans to seek approval for orforglipron to treat Type 2 diabetes later this year, as studies indicate it helps improve blood sugar control in diabetic patients, further expanding its market potential.
See More
